Fierce Pharma
OCTOBER 27, 2023
Sanofi acolytes are none too happy with the latest chapter of CEO Paul Hudson’s "Play to Win" strategy. | Sanofi acolytes are none too happy with the latest chapter of CEO Paul Hudson’s "Play to Win" strategy. After unveiling the pivot alongside third-quarter earnings Friday, Sanofi’s stock plunged nearly 20%, with one analyst group suggesting the plan came “at the wrong time.
MedCity News
OCTOBER 27, 2023
While some people question how virtual care can be effective without physical touch, it is clear that in-person appointments are not frequently delivering on developing a comprehensive understanding of a patient’s need and holistic health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 27, 2023
Weight loss contender Mounjaro may be getting Eli Lilly a lot of public attention these days, but the Indiana pharma giant is busy expanding in immunology, too. | Weight loss contender Mounjaro may be getting Eli Lilly a lot of public attention these days, but the Indiana pharma giant is busy expanding in immunology, too.
MedCity News
OCTOBER 27, 2023
Technology is transforming how clinical trials are run. A panel during MedCity News’ INVEST Digital Health conference discussed the tech trends shaping the design and execution of drug studies.
Fierce Pharma
OCTOBER 27, 2023
With the FDA approval of Agamree (vamorolone) to treat Duchenne | Thursday’s FDA approval of Santhera’s Agamree (vamorolone) to treat Duchenne muscular dystrophy (DMD) is just a start. The Swiss company is anxious to see how many disorders the first-in-class corticosteroid can treat.
MedCity News
OCTOBER 27, 2023
While the dawn of a new AI age is certainly exciting, healthcare leaders are still concerned that the industry lacks a comprehensive framework to regulate these new tools. In the absence of these guidelines, healthcare executives are creating their own governance strategies to deploy AI responsibly, executives said during a panel discussion on Thursday at MedCity News’ INVEST Digital Health conference in Dallas.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 27, 2023
The lack of proper healthcare infrastructure, human resources, equipment, and funding can reduce the quality of care in rural hospitals and clinics. It’s crucial to improve the rural healthcare delivery models and provide quality care to the residents.
Fierce Pharma
OCTOBER 27, 2023
Rogue particles turning up in drugs has caused a plethora of recalls in recent years, most recently affecting pharma giants Pfizer and GSK. | Exela is working with the FDA to recall three separate medications—injectable sodium bicarbonate, midazolam and the nutrition additive Elcys—after inspections of leftover samples flagged silicone matter in some vials.
PharmaVoice
OCTOBER 27, 2023
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
Fierce Pharma
OCTOBER 27, 2023
After a quick FDA approval in a subgroup of endometrial cancer patients, GSK is trumpeting a win for its Jemperli that might help the PD-1 inhibitor expand to a broader population. | After a quick FDA approval in a subgroup of endometrial cancer patients, GSK is trumpeting a win for its Jemperli that might help the PD-1 inhibitor expand to a broader population.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
OCTOBER 27, 2023
Femtech was the theme of the INVEST Digital Health Pitch Perfect contest in Dallas this week. Seven companies presented their approaches to addressing women’s health.
Fierce Pharma
OCTOBER 27, 2023
The market battle between Roche’s Vabysmo and Regeneron and Bayer’s Eylea just cranked up a notch. | The fast-growing blockbuster previously showed non-inferiority to Regeneron and Bayer's Eylea in the condition. This approval will expand the showdown between the two rival drugs.
MedCity News
OCTOBER 27, 2023
During a panel at MedCity News’ INVEST Digital Health conference, three executives representing a provider, a payer and a technology vendor shared their thoughts on how to heal the rocky relationship between hospitals and health plans. For instance, one leader encouraged payers and providers not to be afraid to give up some control, and another urged them to build comprehensive risk models.
European Pharmaceutical Review
OCTOBER 27, 2023
According to The Biosimilar Medicines Group, part of Medicines for Europe, a new report by IQVIA indicates there is a window of opportunity for the EU to foster future-proof biosimilar competition. This publication has come in wake of the EU actively reviewing its Pharmaceutical Legislation. Julie Marechal-Jamil, Director Biosimilar Policy & Science at Medicines for Europe stated the report identified “many policy shortcomings that must be addressed now to deliver access to medicines in the
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
OCTOBER 27, 2023
Season 4 launches with a focus on health equity and a conversation with Dr. Alisahah Jackson, system vice president of population health innovation and policy at CommonSpirit Health.
PharmaVoice
OCTOBER 27, 2023
Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.
European Pharmaceutical Review
OCTOBER 27, 2023
A report published by the Policy Exchange has highlighted how The Future Clinical Trials Bill could improve the UK’s approach to the establishment and regulation of clinical trials. The new Bill is part of a range of proposed policies for implementation under the new legislative programme that will be set out in the final session of this Parliament.
Pharmaceutical Technology
OCTOBER 27, 2023
The UK NICE has recommended the use of AbbVie’s foslevodopa–foscarbidopa (Produodopa) for the treatment of advanced Parkinson’s disease.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaTimes
OCTOBER 27, 2023
Around 145,000 people in the UK are living with Parkinson’s disease - News - PharmaTimes
Pharmaceutical Technology
OCTOBER 27, 2023
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia.
PharmaTimes
OCTOBER 27, 2023
The new principles will remove the regulatory burden for MLMD manufacturers - News - PharmaTimes
Pharmaceutical Technology
OCTOBER 27, 2023
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmExec
OCTOBER 27, 2023
Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.
pharmaphorum
OCTOBER 27, 2023
Sanofi will exit consumer health and boost R&D investment Phil.
PharmExec
OCTOBER 27, 2023
Ito discusses how data-driven AI can be utilized by the pharma industry.
MedTechVets
OCTOBER 27, 2023
October 27th, 2023– How can companies support veterans? The simple answer–hire veterans. The military has equipped Veterans with skills that are highly valued in the corporate world. Leadership, work ethic, adaptability, versatility, mission-oriented minds, problem-solving skills, loyalty, relationship-building skills, and a self-starter attitude are just a few of the areas where Veterans excel.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmaVoice
OCTOBER 27, 2023
A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.
pharmaphorum
OCTOBER 27, 2023
Lilly finally gets FDA OK for ulcerative colitis drug Omvoh Phil.
Scott’s Directories
OCTOBER 27, 2023
In the ever-evolving realm of healthcare, the success of recruitment and staffing strategies hinges on the quality of data at one’s disposal. The Alberta physicians directory emerges as a pivotal resource, especially when navigating the intricate healthcare landscape from High Valley in the north to Cardston in the south and Grand Prairie in the west to Vermillion in the east.
pharmaphorum
OCTOBER 27, 2023
Early result backs Regeneron’s deafness gene therapy Phil.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
263 
Let's personalize your content